MONOPHARMA.NS,0P0001RIYV,4000
MONOPHARMA · General/Diversified · NSE
₹41
Current Market Price
Fair Value (DCF)
₹38
Discount to FV
-5.8%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
13%
ROE
—
Debt/Equity
—
WACC
11.1%
Market Cap
₹72.18 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
1.53×
Revenue per ₹ of assets
Revenue CAGR (3Y)
65.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹40.85
Bear case
Discount -55.7%
Base case
Discount -6.2%
Bull case
Discount +22.1%
Ratio Trends
Historical ratio trends for MONOPHARMA are being prepared. Once ready, this section will show multi-year trajectories of ROE, ROCE, margins, leverage, and valuation multiples.
Historical Financials
Historical financials for MONOPHARMA are being prepared. Check back shortly for a 5-year view of revenue, earnings, cash flow, and balance-sheet trends.
Peer Comparison
Peers not yet ranked for MONOPHARMA. Comparable companies and side-by-side valuation will appear here once the peer set is established.
Dividend History
No dividend events recorded for MONOPHARMA in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. MONOPHARMA.NS,0P0001RIYV,4000 (MONOPHARMA.NS) trades at 40.85 vs a model fair value of 38.48, a gap of -5.8%. Piotroski F-score: 4/9. Moa...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MONOPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MONOPHARMA →
Compare
Head-to-head with peers
Compare MONOPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MONOPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.